Morgan Stanley’s Upstream Bio UPB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.35M Buy
635,905
+111,273
+21% +$728K ﹤0.01% 4544
2026
Q2
$3.63M Sell
524,632
-27,977
-5% -$234K ﹤0.01% 4451
2026
Q1
$4.97M Buy
552,609
+430,541
+353% +$7.75M ﹤0.01% 4136
2025
Q4
$3.31M Buy
122,068
+34,533
+39% +$860K ﹤0.01% 4471
2025
Q3
$1.65M Sell
87,535
-11,773
-12% -$183K ﹤0.01% 4899
2025
Q2
$1.09M Buy
99,308
+47,917
+93% +$443K ﹤0.01% 5052
2025
Q1
$315K Buy
51,391
+8,228
+19% +$78.6K ﹤0.01% 5540
2024
Q4
$710K Buy
+43,163
New +$964K ﹤0.01% 5265

Other funds holding UPB

Morgan Stanley's UPB Position: Q3 2026 in Review

Morgan Stanley increased its Upstream Bio (UPB) stake by 21% in Q3 2026, buying an estimated $728K and bringing the position to 635,905 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4544.

Morgan Stanley first reported a position in UPB in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.97M in Q1 2026. 135 funds tracked by Wall St. Rank hold UPB as of Q3 2026.

  • Morgan Stanley held 635,905 shares of Upstream Bio worth $3.35M as of Q3 2026.
  • Morgan Stanley bought 111,273 Upstream Bio shares in Q3 2026, an estimated $728K.
  • Upstream Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #4544 holding.
  • Morgan Stanley first reported a position in Upstream Bio in Q4 2024 and has held it in 8 quarters since.
  • Morgan Stanley's Upstream Bio position peaked at $4.97M in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Upstream Bio as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.